Micron Technology, Inc. MU is among the best-performing technology stocks in the broader equity market amid ongoing macroeconomic challenges and geopolitical tensions. MU stock has delivered a robust 50.6% gain over the past three months. This performance easily beats the broader Zacks Computer and Technology sector, which declined 6.1% in the same period. The stock has also outpaced the gains of ...
Micron Technology, Inc. MU is among the best-performing technology stocks in the broader equity market amid ongoing macroeconomic challenges and geopolitical tensions. MU stock has delivered a robust 50.6% gain over the past three months. This performance easily beats the broader Zacks Computer and Technology sector, which declined 6.1% in the same period. The stock has also outpaced the gains of other major semiconductor players, including STMicroelectronics STM, Intel Corporation INTC and Texas Instruments, Inc. TXN. In the trailing three months, shares of STMicroelectronics, Intel and Texas Instruments have risen 27.8%, 15.3% and 7.8%, respectively. Micron Technology Three-Month Price Return Performance Image Source: Zacks Investment Research Micron Technology has been a key beneficiary of the artificial intelligence (AI) boom, which has driven strong demand for its memory chips. As the demand for memory solutions supporting AI and high-performance computing (HPC) is likely to remain strong, MU is well-positioned to capitalize on this opportunity. This makes the stock a more attractive investment option at present. Micron’s Strong Financial Performance Despite ongoing macroeconomic challenges, geopolitical issues, and trade and tariff wars, Micron Technology’s financials remain rock solid. The memory chip maker kicked off fiscal 2026 on a strong note by reporting overwhelming first-quarter results. In the first quarter, revenues jumped 57% year over year to $13.64 billion, while non-GAAP earnings per share (EPS) rose 167% to $4.78. The top and bottom lines surpassed the Zacks Consensus Estimate by 7.26% and 22.25%, respectively. Micron Technology reported a non-GAAP gross margin of 56.8%, a robust improvement from 39.5% in the year-ago quarter. Non-GAAP operating income increased to $6.42 billion from $2.39 billion in the year-ago quarter. Non-GAAP operating margin expanded to 47% from 27.5%, reflecting the company’s ability to convert strong revenue growth into ...
How can Advanced Micro Devices (NASDAQ: AMD) turn AI design wins and a multi‑billion dollar GPU deal into durable revenue, despite fierce competition from competitors? Watch the video below for key milestones investors should track. *This video was published on Feb. 24, 2026. Continue reading
How can Advanced Micro Devices (NASDAQ: AMD) turn AI design wins and a multi‑billion dollar GPU deal into durable revenue, despite fierce competition from competitors? Watch the video below for key milestones investors should track. *This video was published on Feb. 24, 2026. Continue reading
China’s cybersecurity agency on Tuesday issued a second warning about security and data risks tied to OpenClaw, despite a rush among local governments and tech companies to adopt the artificial intelligence agent amid a nationwide frenzy. At a time when major Chinese cloud service providers were touting easy deployment of OpenClaw to capitalise on its popularity, improper installation and use of t...
China’s cybersecurity agency on Tuesday issued a second warning about security and data risks tied to OpenClaw, despite a rush among local governments and tech companies to adopt the artificial intelligence agent amid a nationwide frenzy. At a time when major Chinese cloud service providers were touting easy deployment of OpenClaw to capitalise on its popularity, improper installation and use of the agent had also led to severe security risks, said the National Computer Network Emergency Response Technical Team/Coordination Center of China (CNCERT), a non-governmental and non-profit cybersecurity technical platform, in a notice published on its WeChat account. Released by Austrian developer Peter Steinberger late last year, OpenClaw is a software that is taking the world by storm for its ability to perform tasks on a user’s behalf, organising and responding to emails, drafting work reports and preparing slide decks. Advertisement CNCERT partly blamed OpenClaw’s security challenges on its ability to perform tasks autonomously, which required high-level permissions that heightened exposure to breaches. The agency said OpenClaw was vulnerable to threats including “prompt injection”, in which attackers embed hidden malicious instructions in webpages which, when read by the software, could trick it into leaking a user’s system keys. OpenClaw’s security challenges are blamed on its ability to perform tasks autonomously, which requires high-level permissions that heighten exposure to breaches. Photo: Shutterstock It was also prone to “operational errors”, in which the agent may misinterpret user commands and unintentionally delete critical information, including emails and important files, potentially causing significant data loss.
March 10 (Reuters) - Citigroup on Tuesday raised its global artificial intelligence capital expenditure and revenue forecasts for 2026-2030, citing faster enterprise demand and adoption. * Citigroup said AI tools are set to advance rapidly,unlocking new enterprise applications and accelerating theadoption of agentic systems and workflows. * It raised its 2026-2030 global AI capex estimates to $...
March 10 (Reuters) - Citigroup on Tuesday raised its global artificial intelligence capital expenditure and revenue forecasts for 2026-2030, citing faster enterprise demand and adoption. * Citigroup said AI tools are set to advance rapidly,unlocking new enterprise applications and accelerating theadoption of agentic systems and workflows. * It raised its 2026-2030 global AI capex estimates to $8.9trillion compared to its earlier forecast of $8 trillion. * Hyperscalers - Amazon, Microsoft, Alphabet and MetaPlatforms - are expected to collectively spend more than $630billion in capital spending this year. * Citi also forecast global AI revenue for 2026-2030 to jumpto $3.3 trillion from its prior forecast of $2.8 trillion. * AI startup Anthropic has projected as much as $26 billionin annualized revenue in 2026, while ChatGPT maker OpenAIreported surpassing a $25 billion run rate, compared with$21.4 billion it generated at the end of last year. * The bank sees underperformance among the hyperscalers asan opportunity to invest, following the AI-driven selloff intechnology stocks last month. * "We believe the market remains focused on challenges ofbringing global data center capacity online, rising financingneeds and intense competition, while overlooking elevatedreturns from these investments and early signs of anenterprise-driven productivity cycle." (Reporting by Kanchana Chakravarty in Bengaluru; Editing by Vijay Kishore)
Valencia’s fire festival and Ukrainian cadets: photos of the day – Tuesday The Guardian’s picture editors select photographs from around the world Lviv, Ukraine Cadets hold a rolled-up Ukrainian flag to mark the country’s national anthem day Photograph: Global Images Ukraine/Getty Images
Valencia’s fire festival and Ukrainian cadets: photos of the day – Tuesday The Guardian’s picture editors select photographs from around the world Lviv, Ukraine Cadets hold a rolled-up Ukrainian flag to mark the country’s national anthem day Photograph: Global Images Ukraine/Getty Images
Ahead of Nvidia's (NVDA) annual GTC developer conference starts next week, CEO Jensen Huang wrote a blog post about artificial intelligence (AI) as the infrastructure of the future. Morning Brief host Julie Hyman and Yahoo Finance Head of News Myles Udland discuss whether GTC can reignite investor enthusiasm for the company, why there's a disconnect between Nvidia's stock and business, and more. T...
Ahead of Nvidia's (NVDA) annual GTC developer conference starts next week, CEO Jensen Huang wrote a blog post about artificial intelligence (AI) as the infrastructure of the future. Morning Brief host Julie Hyman and Yahoo Finance Head of News Myles Udland discuss whether GTC can reignite investor enthusiasm for the company, why there's a disconnect between Nvidia's stock and business, and more. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.
bigjom/iStock via Getty Images Objective Income and capital appreciation Use for Diversifying income holdings Morningstar category Emerging Markets Bond Market review and outlook Emerging-market bonds posted solid gains in the fourth quarter, outperforming bond markets in developed countries. Emerging-market debt continued to benefit from investor demand for yield and a risk-on market environment ...
bigjom/iStock via Getty Images Objective Income and capital appreciation Use for Diversifying income holdings Morningstar category Emerging Markets Bond Market review and outlook Emerging-market bonds posted solid gains in the fourth quarter, outperforming bond markets in developed countries. Emerging-market debt continued to benefit from investor demand for yield and a risk-on market environment that persisted throughout the quarter despite mixed economic signals and ongoing geopolitical conflicts. Regionally, bond markets in Latin America and Africa outperformed during the quarter, while Asian markets lagged. Within emerging markets, bonds denominated in local currencies outperformed those denominated in U.S. dollars, reflecting a weaker U.S. dollar relative to many foreign currencies during the quarter. Meanwhile, sovereign government securities outperformed corporate bonds, and high-yield bonds outpaced investment-grade debt. Market sentiment remained favorable through the end of 2025, supporting double-digit total returns for emerging-market debt for the calendar year. We expect this constructive tone to extend into the first quarter of 2026, thanks to relatively high yields, improved credit quality, and accommodative global monetary policy, along with AI-related capital expenditures providing near-term support for risk assets. However, an ever-evolving geopolitical landscape―including a heavy calendar of national elections in Latin America―creates the potential for elevated geopolitical risk in 2026. As such, we're taking a tactical, highly selective approach to risk management and individual security selection. Contributors and detractors The fund ( JMKAX ) posted a positive return for the quarter and modestly outperformed its benchmark index. Country allocation was the key factor behind the fund’s outperformance of the index, led by overweight positions in Argentina and Ecuador, along with a lack of exposure to the United Arab Emirates and the Philippines. T...
Tesla stock rose early Tuesday, along with its battery supplier, which reported better-than-expected earnings. The move came after Contemporary Amperex Technology Ltd., better known as CATL, the world’s largest lithium-ion battery maker, reported fourth-quarter net income of $3.3 billion on sales of $20.3 billion. CATL stock rose 9.3% in overseas trading.
Tesla stock rose early Tuesday, along with its battery supplier, which reported better-than-expected earnings. The move came after Contemporary Amperex Technology Ltd., better known as CATL, the world’s largest lithium-ion battery maker, reported fourth-quarter net income of $3.3 billion on sales of $20.3 billion. CATL stock rose 9.3% in overseas trading.
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Lumentum Holdings is back in focus after a fresh update to its analyst model lifted the Fair Value estimate from US$571.45 to US$655.55. That shift lines up with a wave of Street commentary pointing to higher price targets, new multi billion dollar customer co...
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Lumentum Holdings is back in focus after a fresh update to its analyst model lifted the Fair Value estimate from US$571.45 to US$655.55. That shift lines up with a wave of Street commentary pointing to higher price targets, new multi billion dollar customer commitments, and attention on AI driven optical demand, even as some firms highlight execution and valuation risks. As you read on, you will see how these changing targets fit into the wider analyst narrative and what signals to watch next. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Lumentum Holdings. What Wall Street Has Been Saying 🐂 Bullish Takeaways Several firms, including Rosenblatt, Barclays, Stifel, Mizuho, Morgan Stanley, UBS, Citi, Needham and Susquehanna, have raised their Lumentum price targets through early 2026, signaling a more constructive stance on the shares. Rosenblatt highlighted Nvidia's planned US$2b equity investment and multi billion dollar purchase commitments with Lumentum as a key support for future capacity access in advanced laser and optical components tied to co packaged optics. Stifel, after recent meetings with Lumentum's CEO and reviewing the latest fiscal Q2 report, moved its price target to US$800 and brought its previously conservative estimates closer to consensus. Morgan Stanley cited a larger optical total addressable market as AI data center investments increase, which it sees as an important context for Lumentum and its peers. Northland, while focused on Ciena, called out suppliers Fabrinet and Lumentum, along with Nokia, as having greater upside potential compared with Ciena's current setup. 🐻 Bearish Takeaways JPMorgan placed Lumentum on a Negative Catalyst Watch in January 2026, signaling concern that upcoming events could challenge the bullish case even as o...
Many clinical-stage biotech stocks have the potential to surge by more than 1,000% if they successfully make the transition to the commercial stage with approved and well-received therapies. But small-cap biotechs are also among the riskiest stocks in the market. For every start-up that succeeds, there will be several similar companies that never make the leap to profitability, nor even get a ther...
Many clinical-stage biotech stocks have the potential to surge by more than 1,000% if they successfully make the transition to the commercial stage with approved and well-received therapies. But small-cap biotechs are also among the riskiest stocks in the market. For every start-up that succeeds, there will be several similar companies that never make the leap to profitability, nor even get a therapy approved by the Food and Drug Administration. Evommune (EVMN +0.61%) could become one of the winners, and its shares are up 54% so far this year. What is Evommune's edge? This small-cap biotech, which is focused on developing treatments for autoimmune conditions, went public this past November. Its primary candidate, EVO756, is a potential blockbuster. It's currently in a phase 2b trial testing it as a therapy for severe chronic spontaneous urticaria, a long-term autoimmune condition in which hives and deep tissue swelling can appear without an obvious trigger. Expand NYSE : EVMN Evommune Today's Change ( 0.61 %) $ 0.15 Current Price $ 24.76 Key Data Points Market Cap $776M Day's Range $ 24.76 - $ 26.82 52wk Range $ 13.88 - $ 33.20 Volume 31K Avg Vol 619K Gross Margin 89.32 % Unlike other chronic spontaneous urticaria treatments, which aim to control histamine or IgE antibodies, EVO756 seeks to inhibit MRGPRX2, a kind of "volume knob" on mast cells. This prevents these cells from releasing the inflammatory chemicals that cause hives and swelling. EVO756 is also undergoing phase 2b clinical trials for the treatment of atopic dermatitis. Top-line results from the urticaria trial are expected in Q2, while results from the atopic dermatitis trial are expected in Q3 or Q4. Early data showed a clinical response in 93% of patients after only four weeks of treatment. Analysts at investment bank William Blair estimate that EVO756 could achieve peak sales of $5 billion by 2035 across both indications. Success in chronic spontaneous urticaria alone could allow it to reach blockbus...
Key Points Clinical-stage biotech Evommune is seen as a potential buyout candidate. Its shares are up more than 55% so far this year. Its two pipeline candidates are making good progress in clinical trials. 10 stocks we like better than Evommune › Many clinical-stage biotech stocks have the potential to surge by more than 1,000% if they successfully make the transition to the commercial stage with...
Key Points Clinical-stage biotech Evommune is seen as a potential buyout candidate. Its shares are up more than 55% so far this year. Its two pipeline candidates are making good progress in clinical trials. 10 stocks we like better than Evommune › Many clinical-stage biotech stocks have the potential to surge by more than 1,000% if they successfully make the transition to the commercial stage with approved and well-received therapies. But small-cap biotechs are also among the riskiest stocks in the market. For every start-up that succeeds, there will be several similar companies that never make the leap to profitability, nor even get a therapy approved by the Food and Drug Administration. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Evommune (NYSE: EVMN) could become one of the winners, and its shares are up 54% so far this year. What is Evommune's edge? This small-cap biotech, which is focused on developing treatments for autoimmune conditions, went public this past November. Its primary candidate, EVO756, is a potential blockbuster. It's currently in a phase 2b trial testing it as a therapy for severe chronic spontaneous urticaria, a long-term autoimmune condition in which hives and deep tissue swelling can appear without an obvious trigger. Unlike other chronic spontaneous urticaria treatments, which aim to control histamine or IgE antibodies, EVO756 seeks to inhibit MRGPRX2, a kind of "volume knob" on mast cells. This prevents these cells from releasing the inflammatory chemicals that cause hives and swelling. EVO756 is also undergoing phase 2b clinical trials for the treatment of atopic dermatitis. Top-line results from the urticaria trial are expected in Q2, while results from the atopic dermatitis trial are expected in Q3 or Q4. Early data showed a clinical response in 93% of patients af...
A former Syrian colonel has appeared in a London court to face charges of crimes against humanity in the first prosecution of its kind in England and Wales. Salem Al-Salem is charged with murder and torture, crimes allegedly committed during the Syrian government’s violent crackdown on pro-democracy demonstrations in Damascus in 2011. Al-Salem, who fled to the UK, is alleged to have played a leadi...
A former Syrian colonel has appeared in a London court to face charges of crimes against humanity in the first prosecution of its kind in England and Wales. Salem Al-Salem is charged with murder and torture, crimes allegedly committed during the Syrian government’s violent crackdown on pro-democracy demonstrations in Damascus in 2011. Al-Salem, who fled to the UK, is alleged to have played a leading role in the violence at the start of the uprising against Bashar al-Assad, which led to a civil war and the eventual overthrow of Assad’s regime in 2024. The 58-year-old faces three counts of murder as a crime against humanity, three of torture and one of conduct ancillary to murder. The crimes are alleged to have happened while Al-Salem was serving as a colonel in the Syrian air force intelligence department, leading a group that attempted to quell demonstrations in Jobar, a village on the outskirts of Damascus. Al-Salem appeared at Westminster magistrates court via video link on Tuesday with a breathing tube over his mouth. The court was told he had motor neurone disease and was housebound. The chief magistrate, Paul Goldspring, agreed he did not need to give his name because of his health condition, but refused his lawyer’s request for reporting restrictions to protect his identity. “Naming the defendant would not lead to enhanced risk,” he said. The case marks the first time the Crown Prosecution Service (CPS) has brought charges of murder as a crime against humanity under the International Criminal Court Act 2001. A UK court convicted the Afghan warlord Faryadi Sarwar Zardad in 2005 of a “heinous” campaign of torture and hostage taking. The charges against Al-Salem relate to the murders of Omal Al-Homsi, Nizar Fayoumi-AlKhatib, Mohammed Salim Zahrak Balik and Talhat Dalal in April and July 2011. He is alleged to be responsible for killing three of the victims as part of a “widespread or systematic attack” against civilians. He also faces charges of torture against t...
The company will release earnings results for its third quarter, after the closing bell on Tuesday, March 10. Recent Price Cut & Analysts’ Expectations On Monday, Deutsche Bank analyst cut the price target from $375 to $300, Scotiabank analyst lowered the price target from $220 to $215 and Barclays analyst slashed the price target from $310 to $230. Overall, analysts expect Oracle to post third-qu...
The company will release earnings results for its third quarter, after the closing bell on Tuesday, March 10. Recent Price Cut & Analysts’ Expectations On Monday, Deutsche Bank analyst cut the price target from $375 to $300, Scotiabank analyst lowered the price target from $220 to $215 and Barclays analyst slashed the price target from $310 to $230. Overall, analysts expect Oracle to post third-quarter revenue of $16.9 billion, up from $14.13 billion in the same quarter last year, according to data from Benzinga Pro. Wall Street also anticipates earnings per share of $1.55, compared with $1.47 a year earlier. Section: Technical Analysis The stock is trading 1.2% below its 20-day simple moving average (SMA) and 25.2% below its 100-day SMA, indicating a challenging short-term outlook. Over the past 12 months, shares have increased by 1.21% and are currently positioned closer to their 52-week lows than highs, suggesting potential for recovery. Momentum Indicators The RSI is at 44.62, which is considered neutral territory, indicating a lack of strong momentum in either direction. Meanwhile, the MACD shows a value of -4.7484, with the signal line at -6.5837, suggesting a bullish crossover, which could indicate a potential upward shift. The combination of neutral RSI and a bullish MACD suggests mixed momentum, indicating that traders should watch for potential shifts in price direction. Key Resistance : $165.50 : $165.50 Key Support: $138.50 Debt and Market Strategy Moreover, the broader context of Oracle’s financial health and market strategy was highlighted by high credit default swap levels due to its substantial debt, which exceeds $100 billion. This debt is largely attributed to its aggressive investments in AI technology. Steve Eisman commented on the situation, downplaying the risk of bankruptcy but expressing concerns over the opaque, highly leveraged credit deals in the tech sector. In the AI space, Oracle’s strategic decisions are part of a larger industry trend...
Images By Tang Ming Tung/DigitalVision via Getty Images OptimizeRx ( OPRX ) had a rough few months as the stock dropped from the $20s down to the single digits. A lot of the sell-off has to do with the AI-fear trade, which is probably overdone. OPRX stated that their business should have minimal disruption from AI . However, all may not be well with OPRX. The recent Q4 2025 earnings report provide...
Images By Tang Ming Tung/DigitalVision via Getty Images OptimizeRx ( OPRX ) had a rough few months as the stock dropped from the $20s down to the single digits. A lot of the sell-off has to do with the AI-fear trade, which is probably overdone. OPRX stated that their business should have minimal disruption from AI . However, all may not be well with OPRX. The recent Q4 2025 earnings report provides insights into why there was a sell-off reaction. The report shows some headwinds for the 2026 outlook. I have to admit, my previous call for a 'strong buy' has been an embarrassment, as the stock has sold off drastically since my last OPRX article was written . What I saw then was a low valuation and strong expected growth. While the valuation appeared low, it was deceiving due to the high amount of stock-based compensation that OPRX pays out. Plus, the growth looks stalled for 2026, which likely added to the selling. Insights From the Q4 2025 Earnings Report OptimizeRx's stock didn't sell off because of bad Q4 2025 results. The stock sold off because of cautious guidance for 2026, as possible headwinds could negatively impact the year. OPRX did experience some weakness as Q4 2025 revenue declined by 0.24% yoy to $32 million. However, this did beat analysts' estimates by $1.32 million. The better results were apparent on the company's bottom line. Non-GAAP EPS increased by an impressive 70% to $0.51, beating estimates by $0.29. The gross profit increased by 9% yoy to $24.1 million. Adjusted EBITDA increased 36% yoy to $12 million. OptimizeRx also achieved positive results for the full year in 2025. Revenue increased 19% yoy to a record $109.4 million. Adjusted EBITDA increased 108% yoy to $24.3 million. OPRX attributed its success to its largest and most established clients and to newer customers. The new growth came mostly from mid-tier and long-tail life science companies. While the Q4 and full-year 2025 results look positive, OPRX is experiencing softness in its year-t...
EU chief Ursula von der Leyen on Tuesday said Europe’s turn away from nuclear power had been a “strategic mistake”, as soaring oil prices rekindled concerns about the bloc’s energy vulnerability. Speaking at a nuclear summit in Paris, the European Commission president endorsed a return to atomic energy, saying the European Union would back investments in “innovative nuclear technologies”. “It was ...
EU chief Ursula von der Leyen on Tuesday said Europe’s turn away from nuclear power had been a “strategic mistake”, as soaring oil prices rekindled concerns about the bloc’s energy vulnerability. Speaking at a nuclear summit in Paris, the European Commission president endorsed a return to atomic energy, saying the European Union would back investments in “innovative nuclear technologies”. “It was a strategic mistake for Europe to turn its back on a reliable, affordable source of low-emission power,” she said. Advertisement The US-Israeli strikes on Iran and Tehran’s retaliatory attacks across the Gulf region have upended the world’s energy and transport sectors, virtually halting activity in the strategically vital Strait of Hormuz. EU officials have said the situation is yet to reach the crisis levels hit after Russia invaded Ukraine in 2022. 04:33 Fukushima 15 years on: why Japan’s younger generation is embracing nuclear power Fukushima 15 years on: why Japan’s younger generation is embracing nuclear power But the conflict has rekindled a debate on the bloc’s external dependencies and high energy costs, which European industry has long said hamper competitiveness vis-a-vis Asia and North America.
Tom Werner U.S. consumer spending surged to its highest level in three years during February, but the gains mask a deeper divide between wealthy and lower-income Americans, according to new data from the Bank of America Institute. Debit and credit card spending rose 3.2% year-over-year, with strength appearing across retail and services sectors. However, Liz Everett Krisberg, head of the Bank of A...
Tom Werner U.S. consumer spending surged to its highest level in three years during February, but the gains mask a deeper divide between wealthy and lower-income Americans, according to new data from the Bank of America Institute. Debit and credit card spending rose 3.2% year-over-year, with strength appearing across retail and services sectors. However, Liz Everett Krisberg, head of the Bank of America Institute, told CNBC that the growth reflects “an uneven resilience,” adding that “the K shape is continuing.” The “K-shaped” economy describes a recovery where higher-income households thrive while those at the bottom struggle. Krisberg explained that this divergence can be seen through two lenses: consumer spending patterns and wage growth trends. On the spending front, there is some encouraging news. Lower-income consumer spending nearly quadrupled from 0.3% in January to 1.1% in February, narrowing the gap with higher-income households to its smallest margin in six months. Lower-income households’ spending growth (Bank of America Institute internal data) “Everyone, higher, middle, lower, increased their spending,” Krisberg noted, though she emphasized the improvement was relative rather than absolute. The wage picture tells a more troubling story. Higher-income wages are accelerating above 4%, reaching their strongest level in nearly four years, while middle and lower-income wage growth has cooled by approximately 30 basis points. This has created the widest gap between higher and lower-income wage growth in at least a decade, dating back to the start of the Institute’s data series in 2015. Bank of America’s employment data also diverged from recent government reports showing an unexpected decline of 92,000 jobs. The Institute saw a 1.3% increase in households receiving income, a discrepancy Krisberg attributed to people potentially supplementing wages through gig work or multiple income sources. “Our numbers would tell you that it wasn’t as bad as what the BLS s...
In early March 2026, Apple rolled out a wave of lower-priced hardware, including the US$599 MacBook Neo, US$599 iPhone 17e, and refreshed iPad Air with M4, while also extending its ecosystem into areas like medical imaging and preparing a healthcare-focused presence at the HIMSS 2026 Global Health Conference. By pairing these budget-friendly devices and new professional tools with deeper Apple Int...
In early March 2026, Apple rolled out a wave of lower-priced hardware, including the US$599 MacBook Neo, US$599 iPhone 17e, and refreshed iPad Air with M4, while also extending its ecosystem into areas like medical imaging and preparing a healthcare-focused presence at the HIMSS 2026 Global Health Conference. By pairing these budget-friendly devices and new professional tools with deeper Apple Intelligence integration and expanding production into India and the U.S., Apple is working to widen its installed base while reinforcing its role in areas such as education, healthcare, and high-end computing. We’ll now examine how Apple’s push into budget-friendly, AI-enabled devices reshapes its investment narrative around ecosystem growth and services. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. Apple Investment Narrative Recap To own Apple, you need to believe its massive device base, Services growth, and Apple Intelligence rollout can offset slowing hardware cycles and rising regulatory and geopolitical pressure. The latest push into US$599 AI‑ready devices and deeper healthcare ties is directionally consistent with that story, but it does not materially change the near term tug of war between AI‑driven upgrade optimism and margin risk from tariffs, regulation, and higher component costs. Among the recent announcements, the MacBook Neo stands out: Apple’s first US$599 MacBook, running A18 Pro with Apple Intelligence baked into macOS, sharply lowers the entry price for a “real” Mac. This directly connects to the key catalyst of growing the installed base to feed higher margin Services, while also testing how far Apple can push into budget tiers without sacrificing profitability at a time when memory costs and AI spending are ...
US Existing Home Sales Bounced In February As Mortgage Rates Tumbled Despite tumbling mortgage rates, existing home sales plunged (the most since COVID) in January , with some blaming 'below-normal temperatures' despite The West suffering the biggest declines (and unaffected by the winter storms). Consensus was for a modest 0.8% MoM decline in February (again despite an ongoing drop in mortgage ra...
US Existing Home Sales Bounced In February As Mortgage Rates Tumbled Despite tumbling mortgage rates, existing home sales plunged (the most since COVID) in January , with some blaming 'below-normal temperatures' despite The West suffering the biggest declines (and unaffected by the winter storms). Consensus was for a modest 0.8% MoM decline in February (again despite an ongoing drop in mortgage rates) but sales actually surprised to the upside, rising 1.7% MoM . Perhaps even more notably, January's 8.4% MoM plunge was revised up to a slightly less crazy 5.9% MoM drop ... Source: Bloomberg With the beat and upward revision, existing home sales were down just 1.45% YoY but SAAR topped 4mm (4.09mm) once again... Source: Bloomberg On the bright side, with mortgage rates at their lowest since 2022, existing home sales look set to continue to improve (unless Trump's war triggers more panic in rates)... Source: Bloomberg Mortgage rates fell at the end of last month to 6.09% after President Trump asked Fannie Mae and Freddie Mac to purchase $200 billion in mortgage-backed securities to help lower home-financing costs. The NAR’s monthly housing affordability gauge, which reflects changes in home prices, median income and borrowing costs, stands at the most-favorable reading since 2022. “Housing affordability is improving, and consumers are responding,” NAR Chief Economist Lawrence Yun said in a statement. “Still, there is a long way to go to return to pre-pandemic levels of transaction activity.” The NAR report showed the median selling price rose 0.3% from a year earlier — one of the smallest advances since the pandemic housing frenzy — to $398,000 last month. The inventory of previously owned homes increased 4.9% from a year ago to 1.29 million — the most for any February since 2020. Market analysts see home sales climbing this year, with estimates ranging from 1.7% to 14%, according to a survey by Bloomberg late last year. Tyler Durden Tue, 03/10/2026 - 10:09